Over the past few years, GLP-1 receptor agonists have moved from a niche diabetes treatment to one of the most in-demand drug classes globally. Medicines such as semaglutide and tirzepatide are now widely used not only for type 2 diabetes but increasingly for obesity and metabolic disease. Demand Is Outpacing Supply Global demand for GLP-1 therapies has surged due to increased global trial activity involving GLP-1 comparators, expanding indications and it’s increasing availab